Topical Versus Intravenous Lidocaine in Children With Upper Respiratory Infection Undergoing Anesthesia: A Randomized, Double Blind, Clinical Trial

Babak Gharaei 1; Alireza Jafari 1; Mahtab Poor Zamany 1; Mohammadreza Kamranmanesh 1; Homayoun Aghamohammadi 1; Fatemeh Roodneshin 1; Houman Teymourian 1; Yasmin Khazaie 1; Payman Dadkhah 1

1Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Mohammadreza Kamranmanesh, Anesthesiology Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: + 98-2123602175, E-mail: Mrz_kamranmanesh@yahoo.com

Received: September 9, 2014; Revised: October 23, 2014; Accepted: January 10, 2015

Background: The current randomized double-blind clinical trial aimed to compare the incidence of post-operative cough with intravenous vs. topical lidocaine in children with mild upper respiratory infection (URI) anesthetized with laryngeal mask airway (LMA) in the university-affiliated medical center.

Objectives: To assess the incidence of adverse respiratory event including cough, apnea, laryngospasm, bronchospasm following two different methods of lidocaine administration in anesthetized children with mild URI.

Patients and methods: One hundred and thirty pediatric patients with mild URI (within the previous two weeks) aged between one and six years were enrolled. They were candidates to undergo immediate full ophthalmic examination, and randomly divided into two groups of 65 to receive intravenous (1.5 mg/kg) or topical lidocaine on LMA. Anesthesia was induced with sevoflurane, subsequently LMA was inserted when the patient was in deep anesthesia status and maintained on (50% N2O, 50% O2) and 3% sevoflurane. Spontaneous ventilation was maintained throughout the procedure and LMA was removed in deep anesthesia. Outcomes (cough, laryngospasm, bronchospasm and vomiting) were evaluated peri-operatively and one day post-operation.

Results: One hundred and twenty four patients fulfilled the trial. Cough (primary outcome) was significantly more frequent among those with topical compared with intravenous lidocaine (46% vs. 26%; P = 0.004). The incidence of laryngospasm (32% vs. 27%), bronchospasm (18% vs. 12%), desaturation (18% vs. 12%) and vomiting (5% vs. 2%) was not statistically different between the groups.

Conclusions: The pediatric patients undergoing general anesthesia with LMA with intravenous lidocaine experienced fewer incidence of postoperative cough compared to the ones in the topical lidocaine group.

Keywords: Anesthesia; Child; Lidocaine; Respiratory Tract Infection

1. Background

Upper respiratory infection (URI) and its complications are widely studied (1-6). Conducting anesthesia in pediatric patients with URI is an ongoing dilemma (7). Respiratory adverse events are more frequent in these patients; therefore, several studies are focused on risk assessment (8). The patients anesthetized with laryngeal mask airway (LMA) experienced fewer respiratory adverse events compared to the ones with endotracheal tube (9). Topical lidocaine on LMA was also effective (vs. placebo) to lessen respiratory complications in this specific population (10).

It was hypothesized that intravenous lidocaine compared to its topical application is more effective to reduce the incidence of post-operative cough (primary outcome) in pediatric patients with mild URI undergoing general anesthesia (GA) with LMA. The other adverse events as secondary outcomes (laryngospasm, bronchospasm, apnea and vomiting) that occurred in the two studied groups were also evaluated.

2. Objectives

To assess the incidence of adverse respiratory events including cough, laryngospasm, apnea, bronchospasm following two different methods of lidocaine administration in anesthetized children with mild URI.

3. Patients and Methods

3.1. Inclusion Criteria

The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the study (international registration No. IRTC138812083436N1), and informed written consent was obtained from parents. The inclusion criteria were: children aged between one and six years old with URI within the previous two weeks, American Society of Anesthesiologists (ASA) physical status I, no history of anaphylactic reactions to lidocaine, no history of any respiratory tract infections, absence of respiratory problems, and normal lung function as assessed by physical examination and chest x-ray. The exclusion criteria were: children with any systemic disease, children with previous anesthetic complications, and children with respiratory tract infections or other severe infections within the previous two weeks.

Copyright © 2015, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
consent from parents or guardians of the subjects were obtained. One hundred and thirty pediatric patients were enrolled in this randomized double blind trial. The current study was conducted from January 2011 to May 2012 in Labbafinejad hospital, Tehran, Iran (an affiliated university hospital). All pediatric patients ranged one to six years whose parents reported mild URI symptoms (nasal discharge or congestion, cough, sneeze) within the last two weeks were included. Those with an evidence of axillary temperature more than 38, ill appearance evaluated by anesthesiologist in charge, purulent discharge or sputum or lower respiratory infection (crackle or wheeze), or any other medical condition (respiratory, cardiac or neurologic) were excluded. Patients underwent anesthesia to receive full ophthalmologic examination. These procedures were necessary and further delay would result in deleterious consequences.

3.2. Exclusion Criteria

Patients with a probably difficult airway or hypersensitivity to drugs were not studied. Patients who received hydrocortisone, dexamethasone, or extra atropine and vasopressor were excluded from this study; however, they were reported in Figure 1. Those who required muscle relaxant due to unpredicted surgery plan change or procedures lasting more than an hour were also excluded.

![Flow Diagram Showing Patient Selection, Randomization and Exclusion](image)

3.3. Pre-Operative Evaluation

Diagnosis of URI was based on the symptoms (cough, sneeze, runny nose, nasal congestion) assessed by an anesthesiologists or the history provided by the parents or guardians if they thought that the child had a cold during the past two weeks. On the surgery day, pre-anesthesia symptoms of URI (runny nose, nasal congestion, cough, sneeze and sputum) were evaluated using a questionnaire (scored from one to four) by an anesthesiologist (Appendix 1) (11). Patients with an item scored more than two, were considered to have moderate URI and their surgery was postponed for a later date (four to six weeks later). Mild URI was defined as having all or some symptoms in the questionnaire (Appendix 1), none of which scored more than two. Passive smoking of one parent/s or guardian/s, or any close resident relative was also recorded.

3.4. Randomization and Blinding

Patients were randomly divided into two groups (using the table of random numbers) to receive topical lidocaine on LMA (Well Lead Medical Co., Guangdong, China) designated as group T (0.1 mL/kg of 2% Xylogel, Sina Darou Co. Tehran, Iran) or intravenous lidocaine (group IV) (1.5 mg/kg Lignodic, lidocaine hydrochloride, Caspian, Tamin pharmaceutical, Rasht, Iran) (Figure 1).

To make the study blinded, patients in group T received intravenous normal saline (as placebo) while patients in group IV; lubricating gel (0.1 mL/kg of Lubri-jell; Shafa, Farayand neek laboratories, Iran) was applied on the LMA (as placebo). Therefore, both groups received 0.1 mL/kg of gel (lidocaine or lubricating) on the LMA and a fixed volume of clear fluid (containing lidocaine or normal saline). All drugs were prepared in a separate room by an anesthesiologist, considering the patients’ weight, and then handed over (as a package 2 mL syringe containing 0.1 mL/kg of gel and a 5 mL syringe filled with clear fluid; with no labels) to the anesthesiologist in charge.

3.5. Study Protocol

After placing the patient on the operation table, basic monitoring (heart rate (HR), pulse rate, manual blood pressure, pulse oxymetry and electrocardiogram) was established and the values were recorded. In both groups, anesthesia was induced with sevoflurane (starting from 3% concentration and increasing by 1% every 30 seconds if needed, on discretion of anesthesiologist in charge), nitrous oxide (N₂O) and oxygen (50%, 50%). An intravenous line was placed. Atropine (0.01 mg/kg) and lidocaine or placebo was injected based on the study group. Gel (lubricating or lidocaine) was applied on the tip and sides of the LMA. The LMA was inserted by an anesthesiologist, considering the patient’s weight, and then handed over (as a package 2 mL syringe containing 0.1 mL/kg of gel and a 5 mL syringe filled with clear fluid; with no labels) to the anesthesiologist in charge.
were briefed about the methodology and study protocol. Anesthesia was maintained with sevoflurane (2%-3%) in oxygen and N\textsubscript{2}O (50%, 50%). Muscle relaxant was not utilized and subjects breathed spontaneously throughout the procedure. At the end of the procedure, sevoflurane and N\textsubscript{2}O were discontinued and patient received 100% oxygen. The LMA was removed while the patient was in deep anesthesia (regular breathing, CSI ranged 40 - 60, end expiratory remaining sevoflurane concentration of more than 2.15%). Suctioning of oral secretions prior or after the LMA removal was at the discretion of anesthesiologist in charge. Patients spontaneously breathed 100% oxygen through the face mask until they were fully awake, crying or opening eyes. Then they were turned to a lateral position and then transferred to the recovery room, where they received 3 - 5 L/minute oxygen via their face mask (11).

3.6. Outcome Assessments

Post-operative cough was considered the primary outcome. The severity was scored between one and four (Appendix 2) (11) and immediately assessed by an anesthesiologist when patients emerged from anesthesia, in the recovery room, and one day after discharge. The information one day post-operation was retrieved by a telephone call to the parents or guardians.

3.7. Other Outcomes (Secondary)

Bronchospasm severity was scored from one to four (Appendix 2) and assessed by anesthesiologist during induction, maintenance, emergence from anesthesia to recovery. Apnea was defined as cessation of air flow through the airway lasting more than 10 seconds.

Laryngospasm was considered when anesthesiologist heard stridor sound / seconds lasting more than 10 seconds. Desaturation was scored from one to seven (Appendix 2) and assessed during anesthesia and recovery. Vomiting, re-admission and cardiovascular events were also recorded (Appendix 2).

3.8. Statistical Analysis

Previous studies reported a wide range of incidences for post-operative cough. The authors assume that it was due to various confounding factors, which affect the outcome. Therefore, a pilot study was conducted in line with the current study protocol. Fifty percent of the pilot study pediatric patients (20 patients) with URI (anesthetized with topical lidocaine) experienced post-operative coughs, the most common complication. Based on these findings and assuming 50% postoperative complication reduction with intravenous lidocaine and allowing for a power of 80% and α = 0.05; a sample size of 60 patients in each group was required. Allowing for drop-outs, one hundred and thirty patients were included.

Data were analyzed by SPSS software (version 16). Since the data were parametric, independent t-test or Chi-square test (2) was used; while Wilcoxon Mann-Whitney U-test applied for non-parametric parameters. Level of significance was considered as 0.05.

4. Results

One hundred and thirty subjects were enrolled; there were six drop outs and therefore 124 patients completed the trial Figure 1. Variables were normally distributed. There was no statistically significant difference between the two groups regarding the demographic data (Table 1). The presenting symptoms of patients are depicted in Table 2. There was no statistically significant difference between the presenting symptoms, onset of cold and frequency of passive smoking in the two groups.

Peri-operative adverse events are presented in Table 3. Incidence of cough in the pediatric patients was statistically higher in those who received topical lidocaine (P = 0.004). Other variables including apnea, laryngospasm, bronchospasm, desaturation, and vomiting were not statistically different. None of the subjects experienced cardiovascular events (cardiac arrest, bradycardia, arrhythmia or hypotension which required medication), and they were not re-admitted for deterioration of respiratory conditions.

| Table 1. Comparing Demographic Data Between the Study Groups\textsuperscript{a} |
|------------------------|------------------|------------------|
| Variables              | Group T\textsuperscript{b} | Group IV\textsuperscript{c} |
| Total number of patients | 60               | 64               |
| Age, y                 | 3.8 ± 1.2        | 3.8 ± 1.3        |
| Weight, kg             | 17.4 ± 3.2       | 16.3 ± 3.6       |
| Gender                 |                  |                  |
| Male                   | 29               | 37               |
| Female                 | 31               | 27               |
| Surgery duration, min   | 43 ± 4           | 44 ± 3           |

\textsuperscript{a} Data are presented as mean ± SD or number of patients.

\textsuperscript{b} Group T: patients who received topical lidocaine on LMA.

\textsuperscript{c} Group IV: patients who received intravenous lidocaine.

| Table 2. Presenting Symptoms of Patients With URI on the Day of Surgery\textsuperscript{a} |
|------------------------|------------------|------------------|
| Symptoms               | Group T (n = 60) | Group IV (n = 64) |
| Runny Nose             | 55               | 58               |
| Nose Congestion        | 35               | 35               |
| Sneeze                 | 20               | 18               |
| Cough                  | 8                | 8                |
| Sputum                 | 0                | 0                |
| URI Onset Time, d      | 12 ± 2           | 11 ± 3           |
| Passive Smoker         | 15               | 18               |

\textsuperscript{a} Data are presented as number of patients or mean ± SD.
Table 3. Incidence of Perioperative Adverse Events a

|                     | Group T (n = 60) | Group IV (n = 64) | P Value |
|---------------------|-----------------|------------------|---------|
| **Cough**           |                 |                  | 0.004 b |
| No                  | 32 (54)         | 47 (74)          |         |
| Yes, not troublesome| 20 (33)         | 17 (26)          |         |
| Yes, with desaturation | 8 (13)         | 0                | 0.5     |
| **Laryngospasm**    |                 |                  |         |
| No                  | 41 (68)         | 47 (74)          |         |
| Yes                 | 19 (32)         | 17 (26)          |         |
| **Bronchospasm**    |                 |                  | 0.4     |
| No                  | 49 (82)         | 56 (88)          |         |
| Yes, inspiratory wheeze | 11 (18)       | 8 (12)           |         |
| **Desaturation**    |                 |                  | 0.4     |
| SPO2 More than 95%  | 49 (82)         | 56 (88)          |         |
| SPO2 between 90% - 95% and Spontaneously resolved | 11 (18) | 8 (12) |
| **Apnea**           |                 |                  | 0.3     |
| No                  | 57 (95)         | 63 (98)          |         |
| Yes                 | 3 (5)           | 1 (2)            |         |
| **Vomiting**        |                 |                  | 0.3     |
| No                  | 57 (95)         | 63 (98)          |         |
| Yes, ones           | 3 (5)           | 1 (2)            |         |
| **Cardiovascular Event** | 0             | 0                |         |
| **Re-admission or worsening** | 0          | 0                |         |

a Data are presented as No. (%).

b Statistically significant difference.

5. Discussion

Results of the current study revealed that intravenous lidocaine (1.5 mg/kg) is superior to its topical application (0.1 mL/kg of 2% lidocaine gel) in alleviating postoperative cough in pediatric patients with mild URI undergoing LMA general anesthesia. However, other outcomes were not statistically different between the groups.

Von Ungern-Sternberg et al. (12) showed that adverse respiratory events in pediatric patients with URI were more pronounced and common when the symptoms presented within the last two weeks. Therefore, in this study patients with a history of URI within the last two weeks were included. Gharaei et al. (11) suggested that LMA is a better treatment option than the face mask in pediatric patients with URI undergoing anesthesia for ophthalmic examination. Henceforth, LMA was selected in the current study. Although intravenous induction of anesthesia seems to reduce the adverse events (12), authors believe that inhalational induction causes less discomfort for the child while taking venous access. For this reason anesthesia was induced with sevoflurane in the current research. LMA insertion and removal was performed in deep anesthesia as defined in the previous studies (11).

Several factors will affect the outcomes such as presenting symptoms, kind of anesthesia and surgery, age, and the type of virus which caused URI (13). Authors stratified their patients to have mild symptoms and selected a narrow range of age. Moreover all patients were undergoing similar form of surgery and protocol for anesthesia to decrease the confounding effect of these variables. However, patients’ characteristics, medications as well as virus type are aspects which could have affected the outcomes (13). It is recommended to conduct further studies that concentrate on these confounding factors.

Although Tait et al. (14) showed that glycopyrrolate does not reduce adverse events in children with URI perioperatively; atropine was applied before anesthesia in both groups to protect against possible bradycardia during inhalation induction and to decrease secretions (13).

The incidence of adverse events varies in different studies. Orliaguet et al. (13) reviewed the incidence of laryngospasm and found them in a range of 1/1000 to 20/100. These findings probably included general population of children undergoing anesthesia. However, Schebesta et al. (10) reported that 41% of pediatric patients with URI suffered from intraoperative spasm, bronchospasm and laryngospasm, when they did not receive lidocaine, while it was reduced to 18% when topical lidocaine was administered. In the current study laryngospasm occurred in 26% and 32% of subjects in the intravenous and topical groups, respectively. The high incidence in the current study could be due to the fact that laryngospasm was defined just by hearing stridor in the current study whereas, Schebesta et al. (10) defined stridor when there was no air movement i.e. a complete stridor which was resolved with positive pressure. Moreover, the current study did not apply propofol and fentanyl whereas the aforemen-
tioned researcher utilized 5mg/kg propofol in addition to 3 μg/kg fentanyl after induction with sevoflurane (10).

Schebesta et al. (10) reported 53% postoperative cough incidence in pediatric patients with URI who had not received topical lidocaine; while 12% was reported in topical lidocaine group of the current study. In the current study, cough occurred in 26% of the IV group while it occurred in 46% in the topical group. Patients’ characteristics, viral type, method of induction and possibly the dosage of topical lidocaine may all affect the high incidence of postoperative cough in the current study.

Schebesta et al. (10) applied 0.3 mL/kg of topical 2% lidocaine gel while the current study utilized 0.1 mL/kg to cover the LMA (to avoid any wastage in the oral cavity) and to approximate its intravenous dosage. In the authors experience, to properly cover an appropriate LMA for a child (based on his weight), lower volumes of topical lidocaine (compared to that of Schebesta et al. (10)) was sufficient. Extra gel would just be unused and poured out of the mouth or cover unrelated parts of the oral cavity.

There is controversy over the usage of lidocaine in pediatric patients with URI, however, a growing body of literature focuses on this topic (13). Topical versus intravenous lidocaine acts through different mechanisms to suppress perioperative cough (15). Plasma level of intravenous lidocaine should be more than 3 μg/mL to suppress coughing; this is done by inhibiting central nervous system in general patient undergoing intubation. The efficacy of intravenous lidocaine anti-cough effect seems to be short-lived (15). The procedure lasted less than one hour in the current study and therefore the levels of lidocaine could still induce postoperative cough suppression. Several studies advocated intravenous lidocaine in comparison with other routes, such as spray, in alleviating postoperative cough and airway symptoms (13, 16, 17). Most of the previous studies focused on general population undergoing endotracheal intubation (15-17). Authors assume that in pediatric patients with respiratory inflammation, intravenous lidocaine may have some anti-inflammatory effects (18) which affect post-operative airway symptoms.

Local effects of topical lidocaine are not dependent on its serum levels, mean of plasma level was 0.43 μg/mL, and the serum levels do not influence its efficacy. Therefore, it was unnecessary to depict the lidocaine plasma level between the groups, since the peak time and concentrations, considering inter-individual variability, would undoubtedly differ within and among groups and have no or little clinical importance (15). Some studies have advocated intravenous lidocaine over the inhalational type due to fewer incidence of bronchospasm (13, 19) especially in pediatric patients with hyper-reactive airway, which was confirmed in the current study.

Recent investigation by Serra et al. (20) focused on anti-inflammatory effects of nebulized lidocaine, by inhibiting the up-regulation of pro-inflammatory cytokines, which could be applicable for asthma therapy.

The current study did not include patients with moderate or severe URI symptoms, which was a limitation; moreover, those who received muscle relaxant or other medications such as dexamethasone were excluded. The current study evaluated short elective non-invasive surgeries and the type of virus causing URI was not determined. Therefore, future studies focusing on these caveats will promote the knowledge of safe anesthesia in pediatric patients with URI.

Different concentrations and dosages of topical lidocaine may affect post-operative outcomes; therefore, further investigations are recommended to concentrate on this aspect. Intravenous lidocaine is superior to its topical application in alleviating post-operative cough in pediatric patients with mild URI undergoing LMA anesthesia for ophthalmology examination.

Appendix 1. This sheet was completed by an anesthesiologist on the day of surgery (before anesthesia). Patients with scores more than two in any item, were considered to have moderate URI and were excluded from this study. This sheet was previously applied and presented by same authors (11).

| Items | 
|-------| 
| Do you think that your child has a common cold? |
| Yes | 
| No | 
| When did it start? |
| … Days ago | 
| Does anyone of parents or close relatives smoke at home? |
| Yes | 
| No | 
| Does the child have any one of the following symptoms? |
| A) Runny nose |
| No | 
| Sniffing occasionally |
| Continuously running/sniffing, clear |
| Continuously running/sniffing, purulent |
| B) Nasal congestion |
| No |
| Difficult breathing through nose |
| Mouth breathing |
| C) Sneezing |
| No |
| Occasional |
| Frequent |
| Continuous |
| D) Cough |
| No |
| Occasional cough |
| Frequent cough |
| Continuous cough |
| E) Sputum |
| Dry cough |
| Moist cough, no sputum |
| Clear sputum |
| Purulent sputum |
Appendix 2. This Sheet was Complete by the Anesthesiologist in Charge of the Patient During, Induction and Maintenance, and After Recovery and one day after, Anesthesia. This Sheet was Previously Applied and Presented by Same Authors (II)

Items

Does the patient have any one of the following symptoms? Please specify when it occurred (during induction, maintenance, recovery, or at home)

A) Cough
   No
   Yes, not troublesome
   Yes, interferes with ventilation/oxygenation

B) Bronchospasm
   None

Exspiratory or inspiratory wheeze

Inspiratory and expiratory wheeze

Difficult to ventilate

C) Apnea (no air movement for > 10 s)
   Yes
   No

D) Laryngospasm (inspiratory stridor for > 10 s)
   Yes
   No

E) Desaturation
   Saturation remained > 95%
   Saturation 90% - 95% resolved spontaneously
   Saturation 90% - 95% required treatment
   Saturation 90% - 95% despite treatment
   Saturation < 90% resolved spontaneously
   Saturation < 90% resolved by CPAP (continuous positive airway pressure)
   Saturation < 90% despite intervention

F) Vomiting
   No
   Once
   More than once

G) Hypotension (mean arterial pressure decreased > 20% from base for more than 1 min)
   Yes
   No

H) Arrhythmia (any arrhythmia that needed medication to treat)
   Yes
   No

I) Cardiac arrest
   Yes
   No

Did the symptoms increase, the night after surgery?

Yes
   No

Was the patient readmitted to hospital for respiratory problems within 24 h of anesthesia?

Yes
   No

Acknowledgements

Authors wish to thank all the staff of Labbafinejad Hospital. They also wish to thank Mrs Mokhtari who helped with the administrative jobs.

Authors’ Contributions

Babak Gharaei: Designing, analyzing, and writing the primary Draft; Mohammadreza Kamranmanesh: corresponding author; Alireza Jafari, Homayoun Aghamohammadi, Houman Teymournia, Yasmin Khazaie, Payman Dadkhah, Mahtab Poor Zamany, and Fatemeh Rodnesshin helped with conducting the study, correcting, and improving the final manuscript.

References

1. Barari Sawadkhohi R, Mohammadzade I, Mohammadpour-Mir A, Poor Nasrollah M, Valipour M, Hosseinzadeh F, et al. Prevalence of Acute Lower Respiratory Tract Infections due to Respirovirus in Amirkola Children's hospital, Northern Iran during March 2008-March 2010. Iran Red Crescent Med J. 2012;14(10):680–3.
2. Gorjipour H, Karimi A, Fahimzad A, Shiva F, Fallah F, Shamshiri AR. The Seasonal Frequency of Viruses Associated With Upper Respiratory Tract Infections in Children. Arch Pediatr. 2012;19(1):9–13.
3. Alavi SM, Makvandi M, Fard SN, Alavi L. Human Respiratory Syncytial Virus Infection and its Subgroups Among the Hospitalized Young Children With Acute Respiratory Infection. Jundishapur J Microbiol. 2013;6(6):e6452.
4. Nikfar R, Shamsizadeh A, Makvandi M, Khoshghalib A. Detection of Respiratory Syncytial Virus in Hospitalized Children With Acute Lower Respiratory Tract Infections, Using RT PCR in Ahvaz, Iran. Arch Pediatr Infect Dis. 2013;1(2):118–21.
5. Boloursaz MR, Lotfian F, Aghasoei F, Cheraghvandi A, Khalizadeh S, Farjah A, et al. Epidemiology of Lower Respiratory Tract Infections in Children. J Comp Ped. 2013;5(3):93–8.
6. Yellanthoor RB, Shah VKB. Prevalence of malnutrition among under-five year old children with acute lower respiratory tract infection hospitalized at Udupi District Hospital. Arch Pediatr. 2013;5(5):203–6.
7. Tait AR, Malviya S. Anesthesia for the child with an upper respiratory tract infection: still a dilemma? Anesth Analg. 2005;100(1):59–65.
8. Rachel Homer J, Elwood T, Peterson D, Rampersad S. Risk factors for adverse events in children with colds emerging from anesthesia: a logistic regression. Paediatr Anaesth. 2007;17(2):54–61.
9. Tait AR, Pandit UA, Voepel-Lewis T, Munro HM, Malviya S. Use of the laryngeal mask airway in children with upper respiratory tract infections: a comparison with endotracheal intubation. Anesth Analg. 1998;86(4):706–11.
10. Schebesta K, Guloglu E, Chiai A, Mayer N, Kimerberger O. Topical lidocaine reduces the risk of perioperative airway complications in children with upper respiratory tract infections. Can J Anaesth. 2010;57(8):745–50.
11. Gharaei B, Aghamohammadi H, Jafari A, Razavi S, Kamranmanesh M, Kermamy AS. Use of laryngeal mask airway in children with upper respiratory tract infection, compared with face mask: randomized, single blind, clinical trial. Acta Anaesthesiol Taiwan. 2011;49(4):336–40.
12. von Ungern-Sternberg BS, Boda K, Chambers NA, Rehmam C, Johnson C, Sly PD, et al. Risk assessment for respiratory complications in paediatric anaesthesia: a prospective cohort study. Lancet. 2010;376(9743):773–83.
13. Orlaguet GA, Gall D, Savoldelli GL, Coulougen V. Case scenario: perianesthetic management of laryngospasm in children. Anesthesiology. 2012;116(2):458–71.
14. Tait AR, Burke C, Voepel-Lewis T, Chiravuri D, Wagner D, Malviya S. Glycopyrrolate does not reduce the incidence of perioperative
adverse events in children with upper respiratory tract infections. Anesth Analg. 2007;104(2):265–70.

15. Minogue SC, Ralph J, Lampa MJ. Laryngotracheal topicalization with lidocaine before intubation decreases the incidence of coughing on emergence from general anesthesia. Anesth Analg. 2004;99(4):1253–7.

16. Soltani HA, Aghadavoudi O. The effect of different lidocaine application methods on postoperative cough and sore throat. J Clin Anesth. 2002;14(1):15–8.

17. Takekawa K, Yoshimi S, Kinoshita Y. Effects of intravenous lidocaine prior to intubation on postoperative airway symptoms. J Anesth. 2006;20(1):44–7.

18. Honarmand A, Safavi M. Beclomethasone inhaler versus intravenous lidocaine in the prevention of postoperative airway and throat complaints: a randomized, controlled trial. Ann Saudi Med. 2008;28(1):11–6.

19. Groeben H, Silvanus MT, Beste M, Peters J. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med. 1999;159(2):530–5.

20. Serra MF, Anjos-Valotta EA, Olsen PC, Couto GC, Jurgilas PB, Coutias AC, et al. Nebulized lidocaine prevents airway inflammation, peribronchial fibrosis, and mucus production in a murine model of asthma. Anesthesiology. 2012;117(3):580–91.